Skip to main content

Table 5 Linear regression analyses of baseline values and percent changes in clinical factors affecting the percent change in sd LDL-C levels

From: Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association

  Univariate Multivariate
n βa 95 % CIb p n βc 95 % CIb p
BMI (kg/m2) 46 0.04 −1.07 ~ 1.37 0.8     
Gender (Male = 1, Female = 2) 47 −0.18 −17.18 ~ 4.34 0.24 44 −0.11 −16.4 ~ 8.13 0.5
Age (year) 47 −0.1 −0.72 ~ 0.36 0.5     
Body weight (kg) 47 0.18 −0.13 ~ 0.56 0.22 44 0.03 −0.38 ~ 0.44 0.88
Abdominal girth (cm) 45 0.08 −0.44 ~ 0.74 0.61     
HbA1c (%) 47 0.2 −2.07 ~ 11.1 0.17 44 0.19 −2.54 ~ 11.1 0.21
Uric acid (mg/dL) 47 0.1 −2.45 ~ 5.02 0.49     
TC (mg/dL) 47 −0.42 −0.41 ~ −0.09 0.004 44 −0.43 −0.46 ~ −0.06 0.01
LDL-C (mg/dL) 47 -0.29 −0.34 ~ −0.002 0.05d     
TG (mg/dL) 47 −0.18 −0.12 ~ 0.03 0.23 44 −0.04 −0.09 ~ 0.07 0.8
HDL-C (mg/dL) 47 −0.24 −0.66 ~ 0.06 0.11 44 −0.02 −0.45 ~ 0.41 0.92
sd LDL-C (mg/dL) 47 −0.42 −0.68 ~ −0.14 0.004d     
ApoA-I (mg/dL) 47 −0.22 −0.36 ~ 0.05 0.14e     
CETP (μg/mL) 44 0.29 −0.15 ~ 18.67 0.054 44 0.32 0.27 ~ 20.2 0.04
Pioglitazone use 47 0.02 −14.13 ~ 16.5 0.88     
Change in Body weight (%) 47 0.35 0.05 ~ 4.29 0.02 43 0.43 1.24 ~ 5.26 0.002
Change in HbA1c (%) 47 −0.13 −1.2 ~ 0.23 0.37     
Change in Uric acid (%) 47 0.12 −0.22 ~ 0.56 0.41     
Change in TG (%) 46 0.32 0.01 ~ 0.2 0.03 43 0.26 −0.0001 ~ 0.16 0.05
Change in HDL-C (%) 47 0.011 −0.42 ~ 0.61 0.94     
Change in ApoA-I (%) 46 0.11 −0.31 ~ 1.28 0.48     
Change in CETP (%) 44 0.32 0.03 ~ 0.6 0.03 43 0.46 0.19 ~ 0.66 0.001
  1. astandard regression coefficient
  2. bconfidence interval
  3. cstandard partial regression coefficient
  4. dLDL-C and sd LDL-C were excluded from multivariate analysis, since colinearity among TC, LDL-C and sd LDL-C was found
  5. eApoA-I was excluded from multivariate analysis, since colinearity between HDL-C and ApoA-I was found